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A desmoid  tumour  is  a rare  tumour  occurring  predominantly  in  young  adults.  It  involves
deep  ﬁbromatosis  not  giving  rise  to  secondary  localisations  but  having  considerable  local
aggressive  potential.  The  risk  factors  are  still  poorly  understood.  The  role  of  MRI  in  the
initial  examination  and  monitoring  is  crucial,  all  the  more  so  since  a  new  therapeutic
strategy,  with  initial  monitoring,  is  undergoing  evaluation.
Observation of a case
The  main  aspect  of  Mrs  Q.’s  medical  history  was  an  inﬁltrating  ductal  adenocarcinoma  of
the  left  breast,  with  invasion  of  the  axillary  lymph  nodes,  discovered  when  she  was  aged
38  and  in  the  third  month  of  pregnancy.  It  was  treated  by  neo-adjuvant  chemotherapy
during  her  pregnancy,  then  by  mammectomy  and  axial  lymph  node  dissection,  followed
by  adjuvant  radiochemotherapy.  Two  years  later,  she  underwent  left  breast  reconstruction
with  insertion  of  a prosthesis  and  restoration  of  symmetry  with  a  prosthesis  on  the  right.
Five  years  after  diagnosis  of  the  cancer,  and  3  years  after  the  reconstruction  surgery,  a
mass  appeared  within  the  left  breast  reconstruction.  The  ultrasound  examination  showed
a  well  delineated  intramuscular  mass,  discretely  hypoechoic  compared  with  the  homoge-
neous  subcutaneous  fat.  Microbiopsies  taken  under  ultrasound  were  composed  of  fusiform
cells  with  elongated  nuclei  and  found  to  be  myoﬁbroblasts  with  no  nuclear  abnormality,
arranged  in  bundles  on  a ﬁbrous  base.  Immunohistochemical  analysis  showed  recognition
of  foci  of  myoﬁbroblasts  by  anti-actin  and  anti-beta-catenin  antibodies.  This  indicated  a
probable  desmoid  tumour  (Fig.  1),  which  was  conﬁrmed  by  the  presence  of  a  gene  mutation
encoding  for  beta-catenin.
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Figure 1. Histological sections of a desmoid tumour: a: fusiform cells with undulating or elongated nuclei corresponding to myoﬁbrob-
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clasts, with no nuclear abnormality, arranged in bundles on a ﬁbrou
antibodies.
An  initial  MRI  examination  found  a  well  circumscribed
mass  in  the  left  pectoral  muscle,  measuring  67  mm  high  by
48  mm  wide,  with  a  large  axial  diameter  of  isosignal  inten-
sity  in  T1  weighting  compared  with  the  pectoral  muscle,  a
heterogeneous  hypersignal  in  T2  and  becoming  very  weakly
enhanced  following  injection  of  gadolinium.  The  prosthesis
in  contact  with  the  lesion  was  intact  (Fig.  2a,b,c).
Initial  MRI  and  clinical  monitoring  was  suggested.  The
next  check-up  at  3  months  showed  a  25%  increase  in
the  major  axis  of  the  tumour,  i.e.  progression  accord-
ing  to  the  RECIST  criteria  (Fig.  2  d,e,f). Multi-disciplinary
consultation  resulted  in  deciding  to  start  treatment  with
anti-inﬂammatories  and  to  continue  MRI  monitoring.
Comments
Desmoid  tumours  are  rare,  accounting  for  0.03%  of  all  can-
cers.  Their  incidence  is  assessed  at  two  to  four  per  million
inhabitants  per  year  [1].  They  occur  mostly  in  young  adults.
They  are  locally  aggressive  and  tend  to  recur.  Desmoid
tumours  are  deep  ﬁbromatoses  affecting  musculoaponeu-
rotic  structures,  unlike  superﬁcial  ﬁbromatoses  which  affect
the  fasciae.  They  are  classed  in  three  groups  depending
on  their  location:  abdominal  tumours,  which  inﬁltrate  the
abdominal  wall  (most  often  in  women  during  the  period
of  reproductive  activity  who  are  using  hormone  contra-
ceptives,  or  during  or  after  pregnancy),  intra-abdominal
tumours,  which  invade  the  pelvis,  the  mesentery  and
the  retroperitoneum  (common  in  Gardner’s  syndrome)  and
extra-abdominal  tumours  which  occur  in  the  limbs  (70%),  the
thoracic  wall  (15%)  and  the  mediastinum.  Less  than  0.2%  of
breast  tumours  are  desmoid  tumours  [1].
The  aetiology  and  how  the  growth  of  such  tumours  is
regulated  is  as  yet  poorly  known.  Most  of  them  occur  spo-
radically  (97%);  there  is  mutation  of  the  beta-catenin  gene
in  85%  of  sporadic  tumours.  Other  tumours  occur  in  the
context  of  Gardner’s  syndrome,  or  familial  adenomatous
polyps  (rare  1:1,000,000,  an  autosomal  dominant  disease
related  to  mutations  of  the  APC  gene,  chromosome  5q  21-
22  with  high  penetrance,  involving  polyps  of  the  digestive
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ract  with  a  potential  for  malignant  transformation,  osteo-
as,  cutaneous  events  and  desmoid  tumours)  [2].  Moreover,
he  high  woman/man  ratio  (3/1)  and  the  increase  in  volume
f  the  tumours  during  pregnancy  suggests  that  hormones  are
nvolved,  mainly  the  oestrogens.  Surgery  and  trauma  are
lso  risk  factors  for  these  tumours  occurring.  Twenty-ﬁve
ases  of  desmoid  tumours  associated  with  a  breast  prosthe-
is  have  been  reported  in  the  literature;  but  no  link  has
een  demonstrated  between  the  presence  of  a  prosthesis
nd  the  occurrence  of  a  desmoid  tumour  [3].  They  occur
ore  often  when  the  prostheses  contain  silicone  rather  than
aline  solution.  Approximately  2  years  elapse  between  the
mplantation  of  the  prosthesis  and  the  appearance  of  the
umour  [3].
The  ﬁrst-line  treatment  previously  was  surgery,  possibly
ombined  with  radiotherapy.  However,  the  surgical  results
ere  unpredictable,  with  a  considerable  rate  of  recurrence
t  5  years  (20  to  60%),  and  sometimes  ruinous  as  regards
unction  or  aesthetics.  Several  medical  treatments  have
een  tested  (non-steroidal  anti-inﬂammatory  drugs,  hor-
one  treatment,  interferons,  tyrosinase  kinase  inhibitors
nd  cytotoxic  agents)  with  a  variable  success  rate  [1].  Bon-
alot’s  team  has  shown  stability  of  the  disease  at  5  years
n  half  the  142  non-treated  patients  or  those  treated  with
rugs  [4].  A  new  strategy  is  being  evaluated  consisting  of
nitial  monitoring  then  initiation  of  drug  treatment  if  the
umour  evolves.  In  the  event  of  failure,  surgery,  possibly
ssociated  with  radiotherapy,  could  be  suggested.  Studies
re  underway  to  understand  the  biomolecular  factors  impli-
ated  in  the  evolution  of  ﬁbromatoses  in  order  to  assist  in
creening  patients  with  an  increased  risk  of  evolution,  who
ould  then  be  candidates  for  surgery.
MRI  is  the  major  imaging  examination  in  the  initial  exam-
nation  and  monitoring.  The  MRI  characteristics  of  desmoid
umours  vary  [5].  The  tumour  is  often  poorly  delineated
ith  isosignal  in  T1  weighted  images  relative  to  the  adja-
ent  muscles,  is  of  isosignal  or  hypersignal  intensity  in
2-weighted  images  or  STIR,  and  shows  moderate  to  intense
eterogeneous  enhancement.  Sometimes,  the  tumour  is
ell  delineated  in  hyposignal  in  t1  and  T2  images  with  very
ow  enhancement,  which  indicates  a  predominantly  ﬁbrous
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Figure 2. MRI of the left anterior thoracic wall: initial examination (a, b, c) and monitoring examination (d, e, f). Increase in volume of
the tumour without modiﬁcation of the signal: isosignal in T1 weighting relative to the pectoral muscle, heterogeneous hypersignal in T2
weighting and weak enhancement following injection of gadolinium: a: T1-weighted axial slice; b: T2-weighted axial slice; c: T1-weighted
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voronal slice following injection of gadolinium and fat saturation;
oronal slice following injection of gadolinium and fat saturation.
omponent.  Variation  in  the  T2-weighted  signal  seems  to
epend  on  the  cellularity  [6].  Certain  inconsistent  aspects
an  give  a  clue  to  a  diagnosis  of  ﬁbromatosis:  hypointense
urved  areas  in  T2  weighting  (ﬁbrosis  septa),  the  appear-
nce  of  a  hypointense  pseudocapsule  in  T2-weighted  images
nd  a  hypersignal  in  T2  weighting  less  than  or  equal  to  that
o
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s1-weighted axial slice; e: T2-weighted axial slice; f: T1-weighted
f  the  subcutaneous  fat  [7].  The  kinetics  of  enhancement
f  desmoid  tumours  studied  during  dynamic  sequences  are
ariable,  and  seem  to  depend  on  cellularity;  enhancement
f  a  tumour  rich  in  ﬁbrous  tissues  is  gradual  [6,8,9].  No  cor-
elation  has  been  demonstrated  between  the  size  and  the
ignal:  a  tumour  can  increase  in  size  without  its  signal  being
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modiﬁed.  MRI  does  not  allow  the  evolution  of  the  tumour
to  be  predicted  [8].  During  monitoring,  the  efﬁcacy  of  drug
treatment  is  observed  as  a  reduction  in  size  and  an  increase
in  the  T2-weighted  hyposignal  (appearance  of  ﬁbrous  tissue)
[10].  Finally,  with  injection  of  gadolinium,  tumoral  recur-
rence  can  be  distinguished  from  post-operative  ﬁbrosis.
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